Clinical Report: New Treatments for Sickle Cell Disease

Overview

Advancements in imaging and systemic therapies are transforming the management of sickle cell retinopathy (SCR), a serious complication of sickle cell disease (SCD). The article emphasizes the importance of risk stratification and the evolving landscape of therapeutic approaches for SCR.

Background

Sickle cell disease affects over 100,000 individuals in the U.S. and millions globally, leading to various chronic complications, including retinopathy. As the population with SCD ages due to improved systemic care, understanding SCR's pathophysiology and management becomes increasingly critical for retina specialists. This report highlights the need for routine screening and the integration of advanced imaging techniques in clinical practice.

Data Highlights

Key Findings

• Sickle cell retinopathy (SCR) is a progressive ocular complication of sickle cell disease (SCD).
• Patients with HbSC genotype have a higher risk of developing proliferative sickle cell retinopathy (PSCR) compared to those with HbSS genotype.
• Routine ophthalmic surveillance for SCR should begin at age 10, with tailored follow-up based on genotype and risk.
• Multimodal imaging techniques, including SD-OCT and OCTA, enhance detection and monitoring of SCR.
• Recent data indicate that HbSS patients have a significantly increased risk of retinal vascular occlusions.

Clinical Implications

Detail specific advanced imaging technologies and their benefits in clinical practice.

Conclusion

The evolving understanding of sickle cell retinopathy necessitates a proactive approach in screening and management, leveraging new imaging modalities to improve patient outcomes.

References

1. The ASCO Post, 2019 -- Pilot Study Tests Novel Approach to Gene Therapy for Sickle Cell Disease
2. Bone Marrow Transplantation, 2025 -- Understanding Gene Addition and Editing Strategies for Sickle Cell Disease: Insights from the EHA-EBMT Consensus Document
3. The ASCO Post, 2019 -- FDA Approves Voxelotor for Sickle Cell Disease
4. FDA -- FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease
5. The American Society of Retina Specialists -- Sickle Cell Retinopathy - Patients
6. The ASCO Post — FDA Approves Voxelotor for Sickle Cell Disease
7. FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease | FDA
8. Sickle Cell Retinopathy - Patients - The American Society of Retina Specialists
9. Checking your browser - reCAPTCHA